Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 13 July 2004
Vol. 2004, Issue 241, p. pe30
[DOI: 10.1126/stke.2412004pe30]

PERSPECTIVES

Empowering Targeted Therapy: Lessons from Rituximab

Adam J. Olszewski and Michael L. Grossbard*

Division of Hematology and Oncology, St. Luke's–Roosevelt Hospital and Beth Israel Medical Center, New York, NY 10019.

Abstract: Rituximab, a monoclonal antibody directed against the B cell–specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects. Effective as a single agent against some forms of B cell lymphoma, rituximab also has a chemosensitizing effect, enhancing the efficacy of chemotherapy against other forms of the disease. Although the mechanisms whereby rituximab achieves its effects remain incompletely understood, these seem to involve at least three distinct phenomena: (i) antibody-dependent cell-mediated cytotoxicity, (ii) complement-mediated cell lysis, and (iii) stimulation of apoptosis in target cells. The latter occurs through interaction of complexes of rituximab and CD20 in lipid rafts, with elements of a signaling pathway involving Src kinases. Effector molecules trigger various gene expression events, leading to sensitization of malignant cells to proapoptotic stimuli. Lessons learned from the research on rituximab may be applied to the rational development of antibody-based therapies against other forms of cancer.

*Corresponding author. E-mail: mgrossbard{at}chpnet.org

Citation: A. J. Olszewski, M. L. Grossbard, Empowering Targeted Therapy: Lessons from Rituximab. Sci. STKE 2004, pe30 (2004).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support.
R. A. Siddiqui, K. A. Harvey, G. P. Zaloga, and W. Stillwell (2007)
Nutr Clin Pract 22, 74-88
   Abstract »    Full Text »    PDF »
Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz (2006)
J. Leukoc. Biol. 79, 1157-1165
   Abstract »    Full Text »    PDF »
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
K. D. Lute, K. F. May Jr, P. Lu, H. Zhang, E. Kocak, B. Mosinger, C. Wolford, G. Phillips, M. A. Caligiuri, P. Zheng, et al. (2005)
Blood 106, 3127-3133
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882